.png)
.png)
Clinical Fellow
AlloVir
Disclosure(s): AlloVir: Employee, Stocks/Bonds
Iain Fraser, MD, DPhil leads AlloVir's Phase 3 clinical trial: "Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation." ClinicalTrials.gov Identifier: NCT05179057.
He is a physician-scientist, who trained in pediatric infectious diseases at Boston Children's Hospital. He previously held drug development positions at Merck Research Laboratories and at Abide Therapeutics.